Article
Biochemistry & Molecular Biology
Yang Hai, Ling Zuo, Meng Wang, Ruoyu Zhang, Munan Wang, Li Ren, Congwen Yang, Jianwei Wang
Summary: This study found that icariin has an ameliorative effect on hepatic steatosis induced by polycystic ovary syndrome. It reduces excess testosterone and lipid metabolites, increases the expression of fatty acid oxidation molecules, and decreases lipid synthesis.
Article
Endocrinology & Metabolism
Claire Falzarano, Taylor Lofton, Adjoa Osei-Ntansah, Trinitee Oliver, Taylor Southward, Salim Stewart, Stanley Andrisse
Summary: Recent research has shown a high prevalence of nonalcoholic fatty liver disease (NAFLD) in women with polycystic ovary syndrome (PCOS). Women with normal weight can also develop NAFLD. The majority of studies focus on adult, premenopausal women and little attention has been given to young and adolescent women with NAFLD. Future research should include more diverse populations and study the contribution of excess androgens and insulin resistance to NAFLD risk in women with PCOS of varying weights, ages, and ethnicities.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Review
Biochemistry & Molecular Biology
Julia A. Golubeva, Anna F. Sheptulina, Anastasia Yu. Elkina, Ekaterina O. Liusina, Anton R. Kiselev, Oxana M. Drapkina
Summary: Non-alcoholic fatty liver disease (NAFLD) and arterial hypertension (AH) are common non-communicable diseases worldwide. They often coexist and are associated with each other regardless of the presence of other metabolic factors.
Review
Endocrinology & Metabolism
Dongxu Wang, Bing He
Summary: Polycystic ovary syndrome (PCOS) is a common reproductive, endocrine, and metabolic disorder in women, which increases the risk of nonalcoholic fatty liver disease (NAFLD). This study reviews the prevalence, risk factors, and management of NAFLD in PCOS, aiming to enhance our understanding of this field.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY
(2022)
Review
Endocrinology & Metabolism
Bing Yang, Liqing Lu, Dongmei Zhou, Wei Fan, Lucia Barbier-Torres, Justin Steggerda, Heping Yang, Xi Yang
Summary: Fatty liver disease is a complex liver pathology with various pathogenesis and lack of effective treatments. Hepatokines play important roles in the development of NAFLD and NASH and interact with cytokines or peptides secreted from muscle, adipose tissue, and hepatic stellate cells.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Endocrinology & Metabolism
Dongxu Wang, Nan Nan, Hao Bing, Bing He
Summary: Obese patients with PCOS are more prone to develop NAFLD. Compared to the control group, the obese PCOS group showed significant increases in ALT, AST, CAP, TG, TC, LDL-C, TT, FAI, FIns, and HOMA-IR levels, along with lower HDL-C and SHBG levels. Liver CAP in PCOS patients with obesity was positively correlated with ALT, AST, TG, TT, FAI, FIns, and HOMA-IR, and negatively correlated with SHBG. Logistic regression analysis showed that TG, TT, FIns, and HOMA-IR were risk factors for NAFLD, while TT was an independent risk factor for NAFLD in PCOS patients with obesity.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Review
Immunology
Ke-qian Chen, Bo-yi Ke, Lu Cheng, Xiao-qing Yu, Zong-bao Wang, Shu-zhi Wang
Summary: With the development of the social economy, unhealthy living habits and eating styles are gradually affecting people's health in recent years. NAFLD, as a chronic liver disease, has become an increasingly serious public health problem due to these factors. Inflammasomes, as a protein complex, play a crucial role in the development of NAFLD and other diseases.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Review
Health Care Sciences & Services
Evangelia S. Makri, Eleftheria Makri, Stergios A. Polyzos
Summary: Nonalcoholic fatty liver disease (NAFLD) is a prevalent disease associated with various comorbidities, leading to a socioeconomic burden. Despite the lack of approved pharmacological treatment for NAFLD, combination therapies may be a rational alternative due to the multifaceted pathophysiology of the disease.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Review
Medicine, General & Internal
Hang Gong, Huang Zhong, Hui-Mei Xu, Xiong-Chang Liu, Liang-Ping Li, De-Kui Zhang
Summary: Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease that increases the risk of extrahepatic diseases such as cardiovascular disease and portal vein thrombosis. NAFLD patients have an elevated risk of developing thrombosis in both the portal and systemic circulation. The increased portal pressure is a critical factor in the development of portal vein thrombosis in NAFLD patients. The underlying mechanisms of NAFLD complicated with PVT are not fully understood, and the higher risk of PVT in NAFLD is often overlooked by gastroenterologists.
EUROPEAN JOURNAL OF INTERNAL MEDICINE
(2023)
Article
Endocrinology & Metabolism
Sami Qadri, Noora Ahlholm, Ida Lonsmann, Paola Pellegrini, Anni Poikola, Panu K. Luukkonen, Kimmo Porthan, Anne Juuti, Henna Sammalkorpi, Anne K. Penttila, Roberta D'Ambrosio, Giorgio Soardo, Diana J. Leeming, Morten Karsdal, Johanna Arola, Stergios Kechagias, Serena Pelusi, Mattias Ekstedt, Luca Valenti, Hannes Hagstrom, Hannele Yki-Jarvinen
Summary: This study investigated the impact of obesity on the performance of liver fibrosis biomarkers in NAFLD and found that ADAPT and FIB-4 are the best-performing biomarkers in obese patients, unaffected by body mass index.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Review
Gastroenterology & Hepatology
Jie Ning Yong, Wen Hui Lim, Cheng Han Ng, Darren Jun Hao Tan, Jieling Xiao, Phoebe Wen Lin Tay, Snow Yunni Lin, Nicholas Syn, Nicholas Chew, Benjamin Nah, Yock Young Dan, Daniel Q. Huang, Eunice Xiang Xuan Tan, Arun J. Sanyal, Mazen Noureddin, Mohammad Shadab Siddiqui, Mark D. Muthiah
Summary: This study conducted a time-dependent survival analysis comparing the survival of liver transplant recipients with and without nonalcoholic steatohepatitis (NASH). The overall survival was comparable between NASH and non-NASH patients after liver transplantation. However, NASH patients with higher model for end-stage liver disease scores had worse overall survival.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Endocrinology & Metabolism
Stergios A. Polyzos, Ilias D. Vachliotis, Christos S. Mantzoros
Summary: Nonalcoholic fatty liver disease (NAFLD), sarcopenia, and sarcopenic obesity (SO) are prevalent conditions, especially in the aging population, and there is no approved pharmacologic treatment for all of them. There are various mechanisms linking NAFLD with sarcopenia/SO, including alterations in adipokines, cytokines, hepatokines, and myokines. Observational studies support the association between NAFLD and sarcopenia/SO, with some cohort studies showing higher mortality in patients with both conditions. Treatment considerations for NAFLD and sarcopenia/SO are discussed, with limited evidence suggesting the potential benefits of pioglitazone or vitamin E.
METABOLISM-CLINICAL AND EXPERIMENTAL
(2023)
Review
Gastroenterology & Hepatology
Cheng Han Ng, Daniel Q. Huang, Mindie H. Nguyen
Summary: Nonalcoholic fatty liver disease (NAFLD) affects a large percentage of the adult population worldwide. Recent studies suggest that renaming it to metabolic-associated fatty liver disease (MAFLD) may better reflect its underlying pathophysiology and highlight the higher prevalence of metabolic comorbidities and mortality rates compared to NAFLD.
CLINICAL AND MOLECULAR HEPATOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Yoshihisa Takahashi, Erdenetsogt Dungubat, Hiroyuki Kusano, Toshio Fukusato
Summary: Nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) is a global health issue associated with metabolic syndrome and obesity. Pathological evaluation of liver biopsy specimens is currently the gold standard for diagnosing NAFLD/NASH, but it is subjective and prone to interobserver variations. Artificial intelligence (AI) has emerged as a promising tool in pathology for objective and accurate diagnoses. This review outlines the histopathological characteristics of NAFLD/NASH and discusses previous research on AI-based pathological diagnosis.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL
(2023)
Review
Pharmacology & Pharmacy
Reeju Amatya, Donghee Lee, Kyoung Ah Min, Meong Cheol Shin
Summary: Nonalcoholic fatty liver disease (NAFLD) has become a global epidemic and is the primary cause of chronic liver disease. Without medical intervention, NAFLD can progress to nonalcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma. The progression of NAFLD is influenced by genetics, metabolic disorders, and immunologic factors. Fortunately, extensive research has led to the discovery of potent drug candidates, and efforts have been made to improve their druggability. This review provides an overview of clinical trial drug candidates and discusses strategies for developing better drugs.